Adrian Jubb has been appointed chief medical officer of Palo Alto, CA-based Immune-Onc Therapeutics. Jubb comes to Immune-Onc from Achaogen (NASDAQ: [[ticker:AKAO]]), where he was vice president and head of early development. Immune-Onc also appointed An Song to serve as senior vice president of development sciences. Song most recently worked at Genentech as a senior director in the company’s research and early development organization. In addition to the executive appointments, Immune-Onc announced a $33 million Series B round of financing to advance its preclinical drug pipeline. The company’s lead drug candidate, IO-202, is being developed as a potential treatment for acute myeloid leukemia and other cancers.
